Biodexa Pharmaceuticals Plc (BDRX) AI Stock Analysis

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on addressing unmet medical needs. Its leading development program is eRapa™, which is poised for a pivotal Phase 3 registration study targeting familial adenomatous polyposis (FAP), a rare condition where nearly all patients face progression to colorectal cancer without intervention. In addition to FAP, the company is actively developing treatments for type 1 diabetes as well as various forms of primary and metastatic brain cancers. Biodexa seeks to leverage scientific innovation to develop transformative therapies across its targeted therapeutic areas.

Biodexa's top line has contracted significantly over time, exhibiting a 5-year revenue CAGR of -27.8% from FY2018 to FY2023. Annual revenue fell from $674,000 in FY2019 to $343,000 in FY2020, rose to $578,000 in FY2021 and $699,000 in FY2022, before dropping 45.5% to $381,000 in FY2023. Over this period, net income remained negative, registering -$10.1M in FY2019 and -$7.1M in FY2023, while FY2023 operating margin was -2103.4%. For the trailing twelve months ended June 30, 2026, revenue stood at $83,000, as quarterly revenue fell 64.1% year-over-year. TTM earnings per share was $63.74, with both operating margin and profit margin at 0.0%.

As of June 30, 2026, Biodexa reported cash and short-term investments of $3.2M, total assets of $12.6M, and shareholders' equity of $9.6M. The company maintains short-term liquidity with a current ratio of 2.41. Operating cash flows have historically been negative, including -$6.8M in FY2023 alongside free cash flow of -$7.1M. Capital expenditures for FY2025 were $1,956, while the company spent $4.1M on research and development expenses in FY2023.

At its last close of $0.46 on October 16, 2026, Biodexa carried a market capitalization of $1.0M and an enterprise value of -$10.6M. The stock trades at a trailing price-to-sales multiple of 0.6x and a price-to-book multiple of 0.1x, below the 4.1x price-to-sales median of its US-listed Healthcare peers. Its enterprise value to revenue ratio stands at 4.7x. Over the past year, BDRX shares dropped 98.9%, significantly lagging the 16.8% gain for the S&P 500 (SPY). Over a 5-year timeframe, the stock declined 100.0% compared to an 83.0% gain for the benchmark.

One analyst covers Biodexa Pharmaceuticals for the next fiscal year. The mean price target is $8.97, representing a 1867.5% premium to the last close of $0.46. For the current fiscal year ending December 31, 2026, consensus estimates project $0 in revenue and an EPS estimate of $0.00. For the next fiscal year, estimates also call for $0 in revenue and an EPS of $0.00. Biodexa has recorded 0 EPS beats over the last 4 quarters.

This page is an AI-written research summary of Biodexa Pharmaceuticals Plc (BDRX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BDRX income statement, BDRX balance sheet, BDRX key metrics, BDRX analyst forecast, BDRX chart. See the BDRX stock overview for the latest quote and news.